Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases
Nexentis Technologies Inc. announced that its subsidiary MitoCareX Bio has completed an extensive structural analysis of human SLC transport proteins beyond the mitochondrial SLC25 family. Using the proprietary MITOLINE® platform, this enables expansion into virtual screening of novel drug candidates for hard-to-treat cancers and inflammatory metab…